CNTB — Connect Biopharma Holdings Share Price
0.000.00%
Last trade - 00:00- $45.67m
- -$48.04m
- $26.03m
- 34
- 53
- 30
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 0.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.19% | ||
| Return on Equity | -16.14% | ||
| Operating Margin | -86.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 26.03 | n/a | 10.02 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 23rd, 2015
- Public Since
- March 19th, 2021
- No. of Shareholders
- 1,331
- No. of Employees
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 55,349,208
- Address
- 3580 Carmel Mountain Road, Suite 200, SAN DIEGO, 92130
- Web
- https://www.connectbiopharm.com
- Phone
- +1 8587271040
- Contact
- David Szekeres
- Auditors
- CBIZ CPAs P.C.
Upcoming Events for CNTB
Similar to CNTB
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Connect Biopharma Holdings share price?
As of Today at 20:03 UTC, shares in Connect Biopharma Holdings are trading at $0.83. This share price information is delayed by 15 minutes.
How has the Connect Biopharma Holdings share price performed this year?
Shares in Connect Biopharma Holdings last closed at $0.83 and the price had moved by -46.77% over the past 365 days. In terms of relative price strength the Connect Biopharma Holdings share price has underperformed the S&P500 Index by -52% over the past year.
What are the analyst and broker recommendations for Connect Biopharma Holdings?
The overall consensus recommendation for Connect Biopharma Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Connect Biopharma Holdings dividend yield?
Connect Biopharma Holdings does not currently pay a dividend.
Does Connect Biopharma Holdings pay a dividend?
Connect Biopharma Holdings does not currently pay a dividend.
When does Connect Biopharma Holdings next pay dividends?
Connect Biopharma Holdings does not currently pay a dividend.
How do I buy Connect Biopharma Holdings shares?
To buy shares in Connect Biopharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Connect Biopharma Holdings?
As of the previous close price of $0.83, shares in Connect Biopharma Holdings had a market capitalisation of $45.67m.
Where are Connect Biopharma Holdings shares listed?
Here are the trading details for Connect Biopharma Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CNTB
What kind of share is Connect Biopharma Holdings?
Based on an overall assessment of its quality, value and momentum Connect Biopharma Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Connect Biopharma Holdings share price forecast for 2025?
The analyst consensus target price for shares in Connect Biopharma Holdings is $6.00. That is 627.12% above the last closing price of $0.83.
Analysts covering Connect Biopharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
Find out moreWhat is the trend in the Connect Biopharma Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Connect Biopharma Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -29.76%.
As of the last closing price of $0.83, shares in Connect Biopharma Holdings were trading -21.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Connect Biopharma Holdings PE Ratio?
The Connect Biopharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Connect Biopharma Holdings?
We do not have data on Connect Biopharma Holdings' directors